查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571451

原发性免疫力缺乏症候群市场规模、份额和趋势分析报告：按疾病、治疗方法、地区和细分市场预测，2024-2030

Primary Immunodeficiency Disorders Market Size, Share & Trends Analysis Report By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders), By Treatment, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

原发性免疫力缺乏症候群市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球原发性免疫力缺乏症候群市场规模将达111.4亿美元。

预计2024年至2030年复合年增长率为6.4%。由于几个关键因素，该行业正在经历显着成长。遗传病患病率的不断上升、医疗保健专业人员意识的提高以及诊断和治疗技术的进步对于该行业的扩张至关重要。

2022 年 12 月在《新英格兰医学日誌》上发表的一项研究强调了基因治疗治疗 Artemis 缺陷型严重联合免疫力缺乏(ART-SCID) 的成功。透过将 DCLRE1C 基因的健康拷贝添加到患者的干细胞中，这种治疗方法有效地恢復了 T 细胞和 B 细胞的功能。这项针对 10 名婴儿进行的研究表明，与传统治疗相比，免疫系统显着恢復，併发症也更少。儘管研究人员对这种治疗方法的潜力持乐观态度，但仍需要进一步的长期研究和广泛的临床试验来考虑 FDA 的核准及其对不同人群的适用性。 Artemis 缺陷型 SCID 基因疗法的成功证明了对先前难以治疗的疾病的有效治疗，并支持了产业发展。这项进步将推动对基因治疗解决方案和治疗创新的需求。这项研究的积极成果可能会导致投资增加、广泛采用和新治疗方法的开发，从而扩大先进治疗方法的行业。

此外，几种药物的成功凸显了类似创新的潜力，促进了产业扩张并鼓励该领域专业治疗方法的进一步开发。例如，2023年3月，Pharming Group的reniolisib（Joenha）被FDA核准作为首个治疗12岁及以上病患的活化磷酸肌醇3激酶Delta症候群（APDS）的药物。这项核准是在一项为期 12 週的试验之后进行的，该试验表明，与安慰剂相比，reniolisib 减少了淋巴结大小，并将初始 B 细胞计数提高了 37%。基因疗法的进步和雷尼奥利西等新治疗方法的核准正在扩大该行业。这些创新代表了以前难以治疗的疾病的有效解决方案，并推动了对该领域的投资和兴趣的增加。这些治疗方法的成功增强了市场信心并鼓励专门治疗方法的进一步发展。随着研究的进步和新治疗方法的出现，先进的免疫力缺乏治疗市场预计将继续强劲增长，最终使患者和医疗保健提供者受益。

原发性免疫力缺乏症候群市场报告亮点

  • 按地区划分，北美市场占有率最大，2023年为45.39%。该市场是由该地区强大的医疗基础设施、高患病率和积极的政府倡议推动的。
  • 依疾病分，抗体缺乏比例最大，2023年为52.62%。这种增长是由于高盛行率、对医疗保健的重大影响以及针对性治疗方法的开发。意识的提高和先进的诊断技术也提高了我们在行业中的影响力。
  • 依治疗方法，免疫球蛋白替代疗法所占份额最大，2023年占63.18%。对有效治疗的高需求、治疗的进步以及对持续治疗的迫切需求正在促成巨大的市场份额。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章原发性免疫力缺乏症候群市场变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 原发性免疫力缺乏症候群市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章原发性免疫力缺乏症候群市场：疾病估计与趋势分析

  • 细分仪表板
  • 原发性免疫力缺乏症候群市场：疾病波动分析
  • 原发性免疫力缺乏症候群市场：依疾病分类的前景
  • 2018-2030 年市场规模与预测/趋势分析
  • 抗体缺乏
  • 细胞介导的免疫力缺乏
  • 先天性免疫疾病
  • 其他的

第五章原发性免疫力缺乏缺陷症候群市场：治疗方法估计和趋势分析

  • 细分仪表板
  • 原发性免疫力缺乏症候群市场：治疗方法变异分析
  • 原发性免疫力缺乏症候群市场：按治疗方法的前景
  • 2018-2030 年市场规模与预测/趋势分析
  • 免疫球蛋白替代疗法
  • 抗生素治疗
  • 干细胞/骨髓移植
  • 基因治疗
  • 其他的

第六章原发性免疫力缺乏缺陷症候群市场：区域估计与趋势分析

  • 区域仪表板
  • 原发性免疫力缺乏症候群市场：区域变化分析
  • 原发性免疫力缺乏症候群市场：区域展望
  • 2018-2030 年市场规模与预测/趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
    • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争格局

  • 市场参与企业分类
  • 主要企业简介
    • Baxter International, Inc.
    • CSL Behring LLC
    • Takeda Pharmaceutical Company Limited
    • Octapharma
    • Biotest AG
    • Grifols, SA
    • Kedrion Biopharma Inc
    • Bio Products Laboratory Ltd
    • LFB SA
    • ADMA Biologics, Inc.
    • Abbott Laboratories
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-444-4

Primary Immunodeficiency Disorders Market Growth & Trends:

The global primary immunodeficiency disorders market size is expected to reach USD 11.14 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2024 to 2030. The industry is experiencing significant growth, driven by multiple key factors. Rising incidences of genetic disorders, increased awareness among healthcare professionals, and advancements in diagnostic and therapeutic technologies are pivotal in expanding the industry.

A study published in The New England Journal of Medicine in December 2022 highlights the success of gene therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). By adding a healthy copy of the DCLRE1C gene to patients' stem cells, this therapy effectively restored T and B cell function. The study, involving 10 infants, showed significant immune recovery and reduced complications compared to traditional treatments. Researchers are optimistic about the therapy's potential, though further long-term studies and broader trials are needed for FDA approval and to explore its applicability in diverse populations. The successful gene therapy for Artemis-deficient SCID boosts industry growth by demonstrating effective treatment for previously difficult-to-treat conditions. This advancement drives demand for gene therapy solutions and innovations in treatments. The positive outcomes from this study potentially leading to increased investment, broader adoption, and the development of new therapies, thereby expanding the industry for advanced treatments.

Moreover, several drug's success highlights the potential for similar innovations, fostering industry expansion and encouraging further development of specialized therapies in the sector. For instance, in March 2023, Pharming Group leniolisib (Joenja) approved by the FDA as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. The approval follows a 12-week study demonstrating that leniolisib reduced lymph node size and improved naive B cell counts by 37% compared to placebo. The industry is expanding due to advancements in gene therapy and the approval of new treatments such as leniolisib. These innovations demonstrate effective solutions for previously difficult-to-treat conditions, driving increased investment and interest in the sector. The success ofthese therapies boosts market confidence and encourages further development of specialized treatments. As research progresses and new therapies emerge, the market for advanced immunodeficiency treatments is expected to continue its robust growth, ultimately benefiting patients and healthcare providers alike.

Primary Immunodeficiency Disorders Market Report Highlights:

  • Based on region, North America accounted for largest market share of 45.39% in 2023. The market is driven by robust healthcare infrastructure, high prevalence, and proactive government initiatives in the region.
  • Based on disease, antibody deficiency segment accounted for the largest share of 52.62% in disease segment in 2023. The growth can be attributed to its high prevalence, significant healthcare impact, and the development of targeted treatments. Increased awareness and advanced diagnostics also contribute to its substantial presence in the industry.
  • Based on product, the immunoglobulin replacement therapy segment holds the largest share in the market accounted for 63.18% in 2023 owing to its essential role in managing antibody deficiencies. High demand for effective treatment, advancements in therapy, and the critical need for ongoing care contribute to its substantial market share.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Treatment
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Treatment outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Primary Immunodeficiency Disorders Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Primary Immunodeficiency Disorders Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Primary Immunodeficiency Disorders Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
  • 4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Antibody Deficiency
    • 4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Cellular Immunodeficiency
    • 4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Innate Immune Disorders
    • 4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Primary Immunodeficiency Disorders Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
  • 5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Immunoglobulin Replacement Therapy
    • 5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Antibiotic Therapy
    • 5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Stem Cell/Bone Marrow Transplantation
    • 5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Gene Therapy
    • 5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
  • 6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. North America
    • 6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Europe
    • 6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. UK
      • 6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Germany
      • 6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. France
      • 6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.10. Italy
      • 6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.11. Spain
      • 6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.12. Denmark
      • 6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.13. Norway
      • 6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.14. Sweden
      • 6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East & Africa
    • 6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. Baxter International, Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Disease benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. CSL Behring LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Takeda Pharmaceutical Company Limited
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Octapharma
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Biotest AG
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Grifols, S.A.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Kedrion Biopharma Inc
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Bio Products Laboratory Ltd
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. LFB S.A
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. ADMA Biologics, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Abbott Laboratories
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Astellas Pharma Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 4 Global primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 North America primary immunodeficiency disorders market, by region, 2018 - 2030 (USD Million)
  • Table 6 North America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 7 North America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 9 U.S primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 11 Canada primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Mexico primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Europe primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 15 Europe primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Europe primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 UK primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 18 UK primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 21 France primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 22 France primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 23 Italy primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 24 Italy primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Spain primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 26 Spain primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Denmark primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 28 Denmark primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 29 Norway primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 30 Norway primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Sweden primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Sweden primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 37 Japan primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 China primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 39 China primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
  • Table 40 India primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 41 India primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 43 Australia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 South Korea primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 45 South Korea primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 Thailand primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Thailand primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Latin America primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 49 Latin America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 50 Latin America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Brazil primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 52 Brazil primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 54 Argentina primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 South Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 59 South Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 63 UAE primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
  • Table 65 Kuwait primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Primary immunodeficiency disorders market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Primary immunodeficiency disorders market, disease outlook key takeaways, (USD Million)
  • Fig. 12 Primary immunodeficiency disorders market: disease movement analysis, 2023 & 2030 (USD Million)
  • Fig. 13 Antibody deficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Cellular immunodeficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Innate immune disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Primary immunodeficiency disorders market, treatment outlook key takeaways, (USD Million)
  • Fig. 18 Primary immunodeficiency disorders market: treatment movement analysis, 2023 & 2030 (USD Million)
  • Fig. 19 Immunoglobulin replacement therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Antibiotic therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Stem cell/ bone marrow transplantation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Gene therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Primary immunodeficiency disorders market: regional key takeaways (USD Million)
  • Fig. 25 Primary immunodeficiency disorders market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 26 North America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 US Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 UK Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Spain Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Norway Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 China Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 South Korea Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 List of key emerging company's/technology disruptors/innovators